BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting
BioAtla, Inc. (BCAB)
Company Research
Source: GlobeNewswire
SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting to be held in Barcelona, Spain from September 13–17, 2024. Presentation Details: Title:Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)Authors:Winston Wong, Douglas Adkins, Jamal Misleh, Jochen Lorch, Jaspreet Grewal, Jeffery Russell, Jeremy Cetnar, Alan Ho, Kyechin Chen, Kartik Aysola, Jacob ThomasPoster Number:868PSession Type:PosterSession Date and Time:September 14, beginning at 9am CEST A copy of the presentation materials can be accessed on the “Publication” section of the
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla, Inc. (NASDAQ: BCAB) was downgraded by analysts at HC Wainwright from a "buy" rating to a "neutral" rating.MarketBeat
- BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswire
- BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024GlobeNewswire
BCAB
Earnings
- 11/7/24 - Beat
BCAB
Sec Filings
- 11/14/24 - Form SC
- 11/7/24 - Form 10-Q
- 11/7/24 - Form 8-K
- BCAB's page on the SEC website